2 results
Approved WMOCompleted
To prove superiority of Fermathron plus in the treatment of patients with mild knee OA compared to placebo
Approved WMOCompleted
Primary Objective:The primary objective of this study is to compare the efficacy of bimekizumab administered scfor 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects withmoderate to severe chronic plaque PSO.The…